Business Wire

MD-ZEROFOX

Share
ZeroFOX Embraces Partner-First Strategy to Further Accelerate Rapid Growth, Launches New Global Partner Program

ZeroFOX , leader in External Threat Intelligence and Protection, today announced the launch of the ZeroFOX Global Partner Program , a strategic pivot to a partner-first strategy. This move significantly increases ZeroFOX’s investment in partner enablement and commitment to conducting all business with and through their full partner ecosystem.

Another leap forward following the company’s significant expansion of cyber threat intelligence capabilities and addition of three 24/7 global security operations centers (SOCs), ZeroFOX’s partner-first strategy will accelerate capabilities for new and existing customers. Supported by a three-tier structure with escalating benefits, including graduating sales incentives, white glove support and marketing development funds, the Global Partner Program also offers a comprehensive go-to-market toolbox to meet the on-demand needs of a global salesforce. Specialized, entrepreneurial partner organizations with access to strategic geographic and vertical markets will be supported through an incubator program that incentivizes successful marketing initiatives, achieving training goals and overall business velocity.

Gartner forecasts that worldwide IT spending will increase 6.2% this year compared to last, reaching $3.9 trillion. Amid this tech growth, businesses are re-examining their cybersecurity approach. In fact, over half (55%) of tech and security executives plan to increase their cyber budgets this year, according to a recent PwC survey . With remote work and digital dependency – including an influx in social media use driven by the pandemic – contributing directly to this rise in attacks, it’s essential that the cybersecurity industry works to drive resiliency across markets.

“Our partners rely on ZeroFOX’s unmatched pace of innovation and commitment to delivering the world’s strongest external threat intelligence service. Together, we have put ourselves in a position to deliver unrivaled protection, intelligence, and disruption capabilities to all of our customers,” said James C. Foster, CEO of ZeroFOX . “Furthermore, our customers appreciate that as a partner-first organization, we invest in differentiated partner solutions. Our AI platform is a true difference maker for our partners and customers alike.”

With ZeroFOX’s Global Partner Program, partners and MSSPs seeking to increase customer value will be provided a rich set of professional services capabilities that ultimately enrich their core offering. To lead the charge, ZeroFOX has hired a full global partnerships team of channel veterans, including a dedicated team of channel partner directors, solution engineers and marketing experts, led by ZeroFOX Vice President of Global Partnerships, Brian Costello.

“ZeroFOX’s investment in enabling partners through sales, marketing, and technical expertise means that our partners can go-to-market faster, drive more demand, and secure more sustainable sources of revenue,” said Brian Costello, Vice President of Global Partnerships at ZeroFOX . “Both on-demand and white glove programs mean partners can confidently project the value that ZeroFOX brings to their portfolio.”

ZeroFOX expects to double partner contribution to the business this year, already acquiring the company’s largest customer in company history through a partner-based contract. Partners continue to broaden ZeroFOX’s capabilities into several verticals targeted widely by cyber criminals, including healthcare and financial services, and extend the company’s geographic footprint and expansion in EMEA, APAC and LATAM.

“ZeroFOX’s ability to bridge social, mobile, surface, and deep and dark web environments delivers a powerful digital risk protection solution in line with Exclusive Networks UK’s ethos of enabling our Partners to differentiate themselves through innovation and addressing the new challenges faced by end users,” said Mark Parr, Director of Strategic Vendors at Exclusive Networks UK . “Our partnership with ZeroFOX has helped drive growth and uncover new opportunities alongside our diverse range of partners. Furthermore, ZeroFOX's integrations with several of our existing technologies results in the creation of comprehensive and scalable solutions to be adopted by our broad partner base. The synergy between Exclusive Networks UK and ZeroFOX extends beyond technology with both organizations leading with a ‘can do’ approach and continually striving to innovate. This makes working together a natural choice.”

To find out more information about ZeroFOX, please visit our website at www.zerofox.com .

About ZeroFOX – ZeroFOX provides enterprises protection, intelligence and disruption to dismantle external threats to brands, people, assets and data across the public attack surface in one, comprehensive platform. With complete global coverage across the surface, deep and dark web and an Intel-backed artificial intelligence-based analysis engine, the ZeroFOX Platform identifies and remediates targeted phishing attacks, credential compromise, data exfiltration, brand hijacking, executive and location threats and more. The patented ZeroFOX Platform technology processes and protects millions of posts, messages and accounts daily across the social and digital landscape, spanning LinkedIn, Facebook, Slack, Instagram, Pastebin, YouTube, mobile app stores, domains, cloud-based email and more.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye